Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruno Lucidi sold 22,619 shares of the company’s stock in a transaction on Thursday, November 19th. The stock was sold at an average price of $3.94, for a total transaction of $89,118.86. Following the sale, the director directly owned 187,990 shares of the company’s stock, valued at $740,680.60. The trade was a 10.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Bruno Lucidi also recently made the following trade(s):
- On Tuesday, November 17th, Bruno Lucidi sold 6,741 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total transaction of $27,166.23.
Atea Pharmaceuticals Stock Performance
Shares of NASDAQ AVIR traded down $0.06 during mid-day trading on Thursday, reaching $3.93. The company’s stock had a trading volume of 291,342 shares, compared to its average volume of 301,285. The stock has a 50-day moving average of $4.68 and a two-hundred day moving average of $4.94. The stock has a market capitalization of $315.58 million, a P/E ratio of -2.02 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 1-year low of $2.92 and a 1-year high of $6.45.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. Analysts predict that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have recently weighed in on AVIR. Wall Street Zen upgraded Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Morgan Stanley increased their price target on Atea Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Atea Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.00.
Atea Pharmaceuticals News Summary
These are some of the AVIR news items that stood out recently:
- Positive Sentiment: Morgan Stanley increased its price target to $8 from $7. The firm kept an “equal weight” rating, so the higher target is a positive signal but not an endorsement to outperform. Article: Atea Pharmaceuticals Stock Price Expected to Rise, Morgan Stanley Analyst Says
- Negative Sentiment: Directors Bruce Polsky and Bruno Lucidi reported multiple stock sales over the week, totaling about 79,000 shares. Repeated insider selling may weigh on sentiment, although the disclosed transactions do not by themselves indicate why the directors sold. Article: Atea Pharmaceuticals Insider Buying and Selling
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Empowered Funds LLC purchased a new position in Atea Pharmaceuticals during the third quarter worth about $475,000. Engineers Gate Manager LP purchased a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at approximately $78,000. Spark Investment Management LLC purchased a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at approximately $75,000. Headlands Technologies LLC acquired a new stake in shares of Atea Pharmaceuticals during the 2nd quarter worth approximately $77,000. Finally, Wellington Management Group LLP increased its holdings in shares of Atea Pharmaceuticals by 262.7% during the 2nd quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock worth $962,000 after buying an additional 149,776 shares during the last quarter. Institutional investors and hedge funds own 86.67% of the company’s stock.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Recommended Stories
- Five stocks we like better than Atea Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
